CareDx, Inc (CDNA)
After hours:
- Business Wire
Transplant Patients Experience Less Pain and Fewer Adverse Events with CareDx Non-Invasive Testing Solutions
BRISBANE, Calif., September 27, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a new peer-reviewed publication showing that AlloMap®, the industry’s only gene-expression profiling (GEP) blood test to non-invasively assess graft rejection by monitoring immune quiescence in heart transplant patients,1 result
- Business Wire
CareDx Congratulates Board Member Dr. Grace Colón for Being Named Healthcare Innovator on Top 50 Most Powerful Latinas List
BRISBANE, Calif., September 26, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Dr. Grace Colón, a member of its Board of Directors, has been named on the 2022 Most Powerful Latinas list by The Association of Latino Professionals For America (ALPFA).
- Business Wire
CareDx Showcases Transplant Digital Leadership in Patient Care at 2022 MEET Conference
BRISBANE, Calif., September 19, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is convening its annual digital health user conference, Management Expert Exchange in Transplantation (MEET), September 18-20 in Las Vegas, Nevada.
